Document is current

Article History

Received: 6 June 2025

Accepted: 22 June 2025

First Online: 8 July 2025

Declarations

:

: T Mizuno: honoraria for lectures from Astellas and Merck BioPharma. Y Narita: research funding to my institution from Chugai, MSD, Amgen, ONO Pharmaceutical, Astellas, Sanofi, Taiho, Eisai, Daiichi Sankyo, Novartis, and Pfizer; honoraria for lectures, presentations, and speaker bureaus from Yakult Honsha, Taiho, Eli Lilly, Daiichi Sankyo, ONO Pharmaceutical, and Bristol-Meyers Squibb; and participation in the Advisory Board of Daiichi Sankyo. T Masuishi: research funding to my institution from MSD, Daiichi Sankyo, ONO Pharmaceutical, Novartis, Amgen, Syneos Healthe Clinical, Boehringer-Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly, Abbvie, and Merck BioPharma; honoraria for lectures, presentations, and speaker bureaus from Takeda, Chugai, Merck BioPharma, Taiho, Bayer, Lilly Japan, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Bristol-Meyers Squibb, Nippon Kayaku, MSD, Takata, Guardant Health, and Amgen. H Taniguchi: research funding to my institution from Daiichi Sankyo; honoraria for lectures from Ono Pharmaceutical, Taiho, and Takeda. S Kadowaki: research funding to my institution from Ono Pharmaceutical, MSD, Janssen Pharmaceutical, Eli Lilly, Daiichi Sankyo, AstraZeneca, Astellas, Taiho, Nobel Pharmaceutical, Bayer, Chugai, Abbvie, Kyowa Kirin, and Novartis; honoraria for lectures, presentations, and speaker bureaus from Ono Pharmaceutical, MSD, Merck KgaA, Eli Lilly, Bayer, Novartis, Taiho, Daiichi Sankyo, Bristol-Meyers Squibb, Chugai, and Eisai. M Ando: honoraria for lectures, presentations, and speaker bureaus from Eisai, Chugai, Ono Pharmaceutical, and Taiho. M Tajika: honoraria for educational events form Bristol-Meyers Squib and EA Pharma. K Muro: research funding to my institution from Amgen, Taiho, PRA Health Sciences, Chugai, and MSD; consulting fees from Amgen, AstraZeneca, Ono Pharmaceutical, Astellas, and Chugai; honoraria for lectures from Ono Pharmaceutical, Taiho, Bristol-Meyers Squibb, Eli Lilly, MSD, Takeda, and Daiichi Sankyo.

: This study was approved by the Institutional Review Board of Aichi Cancer Center Hospital (Reference Number: 2024-0-515).

: The requirement for individualized informed consent was waived because of the retrospective nature of the study. A committee-approved information disclosure document has been published on the hospital’s website.

: Not applicable.